Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
Status:
Completed
Trial end date:
2016-08-20
Target enrollment:
Participant gender:
Summary
This is a pilot randomized, double-blind, placebo controlled study which will be conducted at
a single center. All participants will receive oral immunotherapy for their specific food
allergies (limited to 5 of those food allergens in IND 14831). In a 3:1 ratio, 36*
participants will receive Xolair for 16 weeks while 12* will receive corresponding placebo
instead of Xolair. 12 controls will be enrolled who will receive no OIT and no Xolair. These
12 controls are not part of the randomization. The total number of participants randomized to
the two arms is 48*.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)